GVP Module VII: PSUR Single Assessment and EU Procedures

Introduction

The European Union periodic safety update system is designed to allow relevant safety information for medicinal products containing the same active substance to be assessed in a coordinated regulatory framework.

The concept of PSUR Single Assessment (PSUSA) is central to this system. It provides a mechanism through which the European regulatory network can perform a coordinated assessment of periodic safety information rather than requiring equivalent safety information to be assessed independently in every relevant national procedure.

Understanding PSUSA requires separating several concepts that are often conflated:

• the PSUR itself;
• submission of the PSUR;
• the PSUSA procedure;
• the assessment report;
• the regulatory outcome;
• and implementation of that outcome by the relevant marketing authorisation holders and authorities.

These are related stages of one regulatory system, but they are not interchangeable terms.

1. What Is PSUR Single Assessment?

PSUR Single Assessment is the EU procedure for assessing periodic safety information relating to medicinal products containing the same active substance or combination of active substances, where the relevant products fall within the applicable EU periodic-reporting framework.

The purpose is to provide a coordinated assessment of the safety information and its implications across the relevant products and marketing authorisations.

The principle is particularly important where the same active substance is marketed through multiple regulatory routes or by multiple marketing authorisation holders.

Without a coordinated assessment, materially similar safety information could potentially be evaluated separately and produce inconsistent regulatory conclusions.

2. PSUR Versus PSUSA

The distinction can be expressed simply:

A PSUR does not become a PSUSA merely because it is submitted to EMA or because the product is centrally authorised.

PSUSA is the regulatory assessment procedure, whereas the PSUR is the evidence and assessment document submitted into the applicable framework.

3. Why the EU Uses a Single-Assessment Approach

The EU contains multiple marketing-authorisation routes and multiple national competent authorities.

The same active substance may therefore appear in:

• centrally authorised medicinal products;
• nationally authorised medicinal products;
• products authorised through mutual recognition procedures;
• products authorised through decentralised procedures;
• or combinations of these situations.

A common safety assessment can reduce unnecessary duplication and promote consistency in the interpretation of important safety information.

This does not eliminate the responsibilities of individual MAHs. Each MAH remains responsible for its own pharmacovigilance system and for complying with the applicable reporting and regulatory obligations.

4. The Regulatory Network

PSUSA operates within the EU pharmacovigilance network.

The relevant participants can include:

• the European Medicines Agency;
• the Pharmacovigilance Risk Assessment Committee (PRAC);
• national competent authorities;
• the European Commission where applicable to the regulatory outcome;
• and the affected marketing authorisation holders.

The precise role of each participant depends on the regulatory procedure and the legal framework applicable to the medicinal product.

The system should therefore not be represented as a simple MAH-to-EMA transaction.

5. The Role of PRAC

The Pharmacovigilance Risk Assessment Committee is the EU committee responsible for the assessment and monitoring of safety issues for human medicines within its legal remit.

Within the PSUSA framework, PRAC plays a central role in the scientific assessment of periodic safety information and in formulating recommendations where required.

The PRAC assessment should be distinguished from the MAH's own scientific assessment contained in the PSUR.

The MAH evaluates its safety information and proposes conclusions. The regulatory network independently evaluates the submitted evidence and determines the appropriate regulatory response under the applicable procedure.

6. The Lead Member State and Assessment Responsibilities

For applicable PSUSA procedures, a designated Member State performs an important assessment role within the EU regulatory network.

The identity and procedural role of the relevant assessor depend on the specific PSUSA procedure and current regulatory arrangements.

The organisation preparing a PSUR should therefore maintain an accurate regulatory record rather than relying on assumptions based on previous procedures.

Changes in regulatory arrangements, products, procedures or responsible authorities should be reflected in controlled regulatory intelligence and submission processes.

7. The Reference Member State and Regulatory History

For nationally authorised products, the regulatory history of the affected marketing authorisations can be complex.

The reference Member State, concerned Member States and other relevant procedural roles may have significance depending on the authorisation history and applicable procedure.

A PSUSA should therefore be understood in the context of the actual marketing authorisation network for the active substance rather than treating all products as though they were authorised identically.

8. Which Products Can Be Included?

The applicable scope is determined by the EU regulatory framework and the active substance or combination involved.

Products containing the same active substance can differ in:

• MAH;
• brand name;
• indication;
• formulation;
• strength;
• route of administration;
• authorisation procedure;
• and Member State distribution.

The existence of these differences does not automatically mean that separate safety assessments are required.

The regulatory framework is designed to enable the relevant information to be assessed together where the products fall within the applicable single-assessment scope.

9. Why Product Differences Still Matter

Although PSUSA promotes coordinated assessment, meaningful product differences remain important to the scientific evaluation.

For example, the clinical significance of a safety issue may depend on:

• indication;
• patient population;
• dose;
• route;
• duration of treatment;
• formulation;
• or specific product characteristics.

The purpose of coordinated assessment is therefore not to erase differences between products. It is to ensure that common evidence is evaluated consistently while clinically relevant differences remain visible.

10. The MAH's Responsibility

Each MAH remains responsible for maintaining an effective pharmacovigilance system and for ensuring that its PSUR is accurate, complete, scientifically sound and submitted according to applicable requirements.

Participation in a PSUSA does not transfer the MAH's pharmacovigilance responsibility to another MAH, another company or the regulatory authority.

Where several MAHs hold products containing the same active substance, each organisation should maintain appropriate controls for:

• identifying its applicable PSUR obligations;
• preparing its submission;
• evaluating its own product information;
• responding to regulatory questions;
• implementing required changes;
• and maintaining evidence of compliance.

11. Multiple MAHs and Shared Safety Information

A shared active substance creates an important distinction between common evidence and individual responsibility.

The same published study, signal or regulatory action may be relevant to multiple MAHs.

However, each MAH must evaluate the implications for its own medicinal products and applicable indications.

A company should not simply copy another MAH's safety conclusion because both products contain the same active substance.

The scientific evidence may be common while the product-specific interpretation may differ.

12. Regulatory Scope Before PSUR Preparation

Before preparing the PSUR, the organisation should establish the applicable regulatory scope.

A controlled scope determination should identify, as appropriate:

1. active substance or combination;
2. applicable EURD entry;
3. reporting interval;
4. DLP;
5. relevant marketing authorisations;
6. applicable regulatory procedure;
7. participating authorities;
8. submission route;
9. and product-specific considerations.

This prevents a common failure mode in which the scientific report is prepared correctly but submitted into an incorrectly understood regulatory framework.

13. PSUSA and the EURD List

The EURD framework is important to the operation of the EU periodic-reporting system.

The current EURD list provides information relevant to the periodic reporting obligations for substances within its scope, including reference dates and reporting frequencies.

The organisation should use the current regulatory information rather than an archived copy of a previous calendar.

Changes to the EURD list can therefore have direct operational consequences for PSUR planning and submission.

14. The Assessment Is Not a Second PSUR

The regulatory assessment does not simply reproduce the MAH's report.

The regulator evaluates the evidence, the analysis and the conclusions and may identify issues requiring clarification or further action.

The resulting assessment can therefore focus on:

• important safety concerns;
• the strength of evidence;
• benefit-risk implications;
• adequacy of risk-management measures;
• product-information implications;
• and consistency across the affected products.

The distinction between submission and assessment is important when designing internal governance and response processes.

15. Practical Scenario: Same Active Substance, Different Indications

Suppose two medicinal products contain the same active substance but are authorised for substantially different indications.

A safety signal identified in one indication may still be relevant to the other, but its clinical importance may differ because the treated populations and expected benefits differ.

The coordinated PSUSA assessment should therefore consider the common evidence while retaining the clinical context of each relevant product or indication.

The MAH should likewise ensure that its own benefit-risk assessment does not assume that a common active substance means identical product-level benefit-risk conclusions.

16. Practical Scenario: Multiple MAHs Reach Different Conclusions

Several MAHs may initially interpret the same safety information differently.

This is not necessarily evidence of poor pharmacovigilance. Scientific assessment can involve legitimate differences in interpretation, particularly where evidence is uncertain.

The purpose of the regulatory assessment is partly to provide an independent evaluation of the totality of evidence and establish the appropriate EU-level regulatory conclusion.

MAHs should nevertheless maintain a documented rationale for their own conclusions and should be able to explain material differences from other organisations' assessments.

17. Practical Scenario: Regulatory Action Affects All Products

A PSUSA may result in a regulatory outcome that requires changes affecting multiple products containing the active substance.

The implementation process then becomes a separate controlled activity.

Each MAH must determine how the regulatory outcome applies to its own marketing authorisations and ensure that the required changes are implemented through the applicable regulatory and pharmacovigilance processes.

A common EU assessment does not remove the need for product-level implementation control.

18. Inspection Perspective

An inspector may ask an MAH:

• How do you identify the PSUSA procedures relevant to your products?
• How do you monitor changes to the EURD framework?
• How do you identify all affected marketing authorisations?
• How do you distinguish common active-substance evidence from product-specific evidence?
• How do you receive and assess PSUSA outcomes?
• How do you implement regulatory actions?
• How do you reconcile the PSUR with the RMP and signal-management system?
• How does the QPPV obtain assurance that PSUSA obligations are controlled?

The organisation should be able to demonstrate the answers using controlled records rather than relying on individual employee knowledge.

Key Takeaways

• A PSUR and a PSUSA are different things.
• The PSUR is the periodic safety report and scientific assessment prepared by the MAH.
• PSUSA is the coordinated EU regulatory assessment procedure.
• Multiple products and MAHs can be brought into a coordinated assessment while retaining individual MAH responsibilities.
• Product-specific clinical context remains important even where the active substance is shared.
• PRAC has a central role in the EU scientific assessment within its legal remit.
• The current regulatory scope and EURD information should be verified before each reporting cycle.
• Regulatory assessment and implementation are distinct stages and require separate controls.
• A coordinated assessment does not transfer pharmacovigilance responsibility away from individual MAHs.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VII — Periodic Safety Update Report.
2. European Medicines Agency. Periodic safety update reports (PSURs) and PSUR Single Assessment (PSUSA).
3. European Medicines Agency. European Union reference dates (EURD) list.
4. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC).
5. European Commission. Commission Implementing Regulation (EU) No 520/2012, as amended.
6. Directive 2001/83/EC, as amended.
7. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article is an educational explanation of PSUR Single Assessment and related EU procedures. It does not replace current EU legislation, GVP Module VII, EMA procedural guidance, the current EURD list, PSUR Repository requirements or an organisation's approved procedures.

Regulatory procedures and guidance may change. Before preparing, submitting or implementing a PSUR or PSUSA outcome, the current applicable regulatory documents and procedural requirements should be verified.

Examples and inspection considerations are illustrative unless an authoritative source is specifically identified.

19. The PSUSA Procedural Flow

The practical PSUSA process can be understood as a sequence of controlled regulatory stages:

Applicable reporting obligation
          ↓
PSUR preparation and submission
          ↓
Regulatory validation
          ↓
Scientific assessment
          ↓
PRAC consideration
          ↓
Recommendation / regulatory conclusion
          ↓
Applicable EU decision process
          ↓
Implementation by affected MAHs
          ↓
Follow-up and pharmacovigilance governance

The exact procedural details depend on the applicable legal framework and product situation. The organisation should therefore use the current EMA procedural information for the specific procedure rather than relying on a generic historical workflow.

20. Submission Does Not Mean Acceptance

Submission of a PSUR is not equivalent to regulatory acceptance of its conclusions.

The submitted report becomes evidence for an independent regulatory assessment. The assessor may agree with the MAH's conclusions, disagree with them, identify uncertainties or request clarification.

The MAH should therefore maintain a controlled process for handling regulatory questions and should not regard completion of the PSUR as the end of the activity.

21. Validation and Procedural Completeness

Before scientific assessment can proceed, the submission must satisfy the applicable procedural and technical requirements.

Potential validation considerations include:

• correct product and substance scope;
• correct reporting interval;
• correct DLP;
• appropriate submission format;
• required documents;
• applicable administrative information;
• and compliance with the relevant submission channel.

A technically defective submission can create avoidable regulatory risk even where the underlying scientific assessment is sound.

22. Scientific Assessment

The assessment examines the information contained in the PSUR and its implications for the safety profile and benefit-risk balance.

The assessment may focus on:

• important new safety information;
• emerging signals;
• changes in known risks;
• exposure and utilisation;
• effectiveness of risk-minimisation measures;
• product-information implications;
• and differences between the submitted conclusions and the assessor's interpretation.

The assessment is therefore an independent scientific review, not an editorial review of the MAH's document.

23. PRAC Recommendation

Where PRAC has responsibility within the applicable procedure, its scientific recommendation forms an important part of the EU regulatory process.

The recommendation can address whether changes are required or whether the current regulatory position remains appropriate.

The MAH should distinguish:

• its own PSUR conclusion;
• the assessor's assessment;
• the PRAC recommendation;
• and the final applicable regulatory decision.

These stages may be closely related but should not be described as though they are the same document or decision.

24. Assessment Report

The assessment report records the regulator's evaluation of the submitted periodic safety information.

It can explain:

• the principal safety issues considered;
• the evidence supporting the assessment;
• the benefit-risk interpretation;
• points of disagreement or uncertainty;
• and the regulatory conclusions or recommendations.

For an MAH, the assessment report is therefore important feedback about how the regulator interpreted the evidence.

It should be incorporated into the organisation's pharmacovigilance governance and regulatory-intelligence processes where relevant.

25. Regulatory Outcome

The regulatory outcome depends on the applicable legal procedure.

Possible outcomes can include:

• no change to the current authorisation conditions;
• changes to product information;
• additional risk-minimisation measures;
• additional pharmacovigilance activity;
• further regulatory assessment;
• safety communication;
• or other measures permitted under the applicable framework.

The outcome should be understood as the result of regulatory assessment rather than simply as an approval or rejection of the PSUR.

26. Implementation of the Outcome

Once a regulatory outcome has been established, the affected MAHs must determine what actions are required for their products.

Implementation can involve:

• regulatory submissions;
• product-information updates;
• safety communications;
• RMP updates;
• additional pharmacovigilance activities;
• updates to internal safety information;
• training or operational changes;
• and monitoring of implementation effectiveness.

The implementation process should have clear ownership, deadlines and evidence of completion.

27. Regulatory Outcome Versus RMP Update

A regulatory outcome does not automatically mean that every component of an RMP must change.

The MAH should assess the implications systematically.

For example:

PSUSA outcome
      ↓
What changed in the safety understanding?
      ↓
Does the safety specification change?
      ↓
Do PV activities change?
      ↓
Does risk minimisation change?
      ↓
Does the RMP require updating?

This prevents both underreaction and unnecessary changes to the risk-management system.

28. Regulatory Outcome Versus Signal Management

A PSUSA outcome can confirm, modify or challenge conclusions reached through the MAH's signal-management process.

The organisation should reconcile the outcome with its internal safety governance.

If a regulatory authority concludes that an issue requires action, the MAH should ensure that the issue is appropriately reflected in its ongoing signal and safety-management processes.

Conversely, a regulatory conclusion that no action is required should not necessarily cause an internal process to be closed without considering the broader evidence and applicable procedures.

29. Regulatory Questions and Requests for Clarification

During assessment, regulators may request additional information or clarification.

The organisation should maintain a controlled process for:

• receiving the request;
• determining ownership;
• assessing the question medically and scientifically;
• preparing the response;
• obtaining appropriate review and approval;
• submitting within the required timeframe;
• and documenting the final response.

The response process should preserve the link between the question, the evidence reviewed and the answer provided.

30. Disagreement With the Regulatory Assessment

A regulator and an MAH may not initially reach the same scientific conclusion.

The appropriate response is a documented scientific and regulatory dialogue rather than an assumption that disagreement itself represents a compliance failure.

The organisation should be able to distinguish:

• factual disagreement;
• methodological disagreement;
• interpretation of clinical significance;
• uncertainty about causality;
• and disagreement about the appropriate regulatory action.

Responses should address the evidence and reasoning rather than simply restating the original PSUR conclusion.

31. Multiple MAHs During the Assessment

Where several MAHs are affected by the same PSUSA, the assessment may consider evidence submitted by different organisations.

Each MAH should nevertheless maintain control of its own information and responses.

Important issues include:

• ensuring that the MAH's own data are complete;
• understanding relevant information from other products;
• identifying product-specific differences;
• reconciling the organisation's conclusions with the regulatory assessment;
• and implementing the outcome for its own products.

A shared active substance does not create a shared corporate responsibility.

32. Practical Scenario: The Regulator Identifies a New Risk

Suppose the PSUR concludes that there is insufficient evidence for a new important risk, but the regulatory assessment concludes that the evidence warrants recognition of the risk.

The MAH should:

1. review the regulatory reasoning;
2. assess the implications for its own products;
3. update internal safety governance as necessary;
4. determine implications for the RMP and product information;
5. implement the required regulatory actions;
6. document the response and completion evidence.

The original PSUR should not be silently rewritten to make it appear that the MAH reached the regulatory conclusion initially.

The regulatory history should remain traceable.

33. Practical Scenario: No Regulatory Action

A PSUSA may conclude that no change is required.

This does not mean that the MAH's pharmacovigilance system stops monitoring the issue.

The organisation should record the regulatory conclusion, assess whether any internal follow-up remains appropriate and continue routine pharmacovigilance according to its procedures.

The conclusion should be treated as part of the evidence base for future periodic assessments.

34. Practical Scenario: Product Information Change

Suppose the regulatory assessment requires a product-information change.

The organisation should establish:

• exactly what change is required;
• which products are affected;
• which regulatory procedure applies;
• submission and implementation deadlines;
• responsible functions;
• and evidence that the change was implemented correctly.

The change should then be incorporated into relevant safety information and future pharmacovigilance activities.

35. Practical Scenario: Different Impact Across Products

A common regulatory outcome may affect products differently because of differences in:

• indication;
• dosage;
• formulation;
• route;
• population;
• or authorised wording.

The MAH should therefore perform a product-specific implementation assessment rather than assuming that one generic action automatically covers every product.

36. Inspection Evidence

For an inspection, the organisation should be able to reconstruct the complete regulatory lifecycle:

EURD / regulatory obligation
        ↓
PSUR preparation
        ↓
Submission
        ↓
Assessment
        ↓
Regulatory outcome
        ↓
Internal impact assessment
        ↓
Implementation
        ↓
Effectiveness / follow-up

Relevant evidence may include:

• submission records;
• validation correspondence;
• assessment reports;
• regulatory questions and responses;
• PRAC recommendations where applicable;
• final decisions;
• impact assessments;
• implementation records;
• RMP/product-information updates;
• and governance minutes.

37. Common Procedural Failures

Potential weaknesses include:

• treating PSUSA as synonymous with PSUR;
• failing to monitor the current procedure;
• inadequate control of regulatory correspondence;
• failing to assess the impact of a regulatory outcome;
• implementing a change without documenting completion;
• failing to reconcile regulatory conclusions with internal safety governance;
• and losing traceability between the PSUR, assessment and final action.

These are illustrative failure modes rather than claims that every example constitutes a regulatory finding.

38. QPPV Oversight

The QPPV should have sufficient visibility of significant PSUSA outcomes and their implications for the pharmacovigilance system.

Important oversight questions include:

• Was the correct procedure identified?
• Was the PSUR submitted on time and in the required form?
• Were important regulatory questions answered adequately?
• Were significant disagreements understood?
• Was the regulatory outcome assessed for impact?
• Were required actions implemented?
• Was the outcome reflected in the wider PV system?

The QPPV should not need to manage every administrative step personally, but should have appropriate assurance that significant regulatory obligations are controlled.

39. Final Procedural Checklist

Before closing a PSUSA-related activity, confirm:

• the applicable procedure is correctly identified;
• the regulatory scope is documented;
• the PSUR was submitted correctly;
• regulatory correspondence is retained;
• assessment conclusions are understood;
• the final regulatory outcome is identified;
• product-specific impact has been assessed;
• RMP implications have been evaluated;
• product-information implications have been evaluated;
• required actions have owners and deadlines;
• implementation is documented;
• and the outcome is incorporated into ongoing PV governance.

Key Takeaways

PSUSA is a coordinated regulatory assessment process, not simply another name for the PSUR.

The MAH prepares and submits the PSUR; the EU regulatory network independently assesses the information and reaches the applicable regulatory conclusion.

The process does not end with assessment. Regulatory outcomes must be translated into controlled product-level implementation, with appropriate consideration of the RMP, product information, safety communication and ongoing pharmacovigilance.

The complete regulatory history should remain traceable from reporting obligation through PSUR, assessment, regulatory outcome and implementation.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VII — Periodic Safety Update Report.
2. European Medicines Agency. Periodic safety update reports (PSURs) and PSUR Single Assessment (PSUSA).
3. European Medicines Agency. PRAC recommendations on signals and periodic safety update procedures.
4. European Medicines Agency. European Union reference dates (EURD) list.
5. European Commission. Commission Implementing Regulation (EU) No 520/2012, as amended.
6. Directive 2001/83/EC, as amended.
7. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article is an educational explanation of PSUR Single Assessment and related regulatory procedures. It does not replace current EU legislation, GVP Module VII, EMA procedural guidance, the current EURD list, PSUR Repository requirements or an organisation's approved procedures.

Regulatory procedures and guidance may change. Before preparing, submitting or implementing a PSUR or PSUSA outcome, the current applicable regulatory documents and procedural requirements should be verified.

Examples and inspection considerations are illustrative unless an authoritative source is specifically identified.

40. Lifecycle Changes During or After a PSUSA

A medicinal product can change while a periodic safety assessment is being prepared or implemented.

Examples include:

• a new indication;
• a new strength or formulation;
• a change in MAH;
• a transfer of marketing authorisation;
• a new risk-minimisation measure;
• a product-information change;
• or a change in the regulatory status of the product.

The organisation should assess whether the change affects the PSUR scope, the interpretation of the evidence, the implementation of the regulatory outcome or future reporting obligations.

A historical PSUSA conclusion should not be assumed to remain applicable without considering subsequent regulatory and product changes.

41. Change of MAH

A change in marketing authorisation holder creates an important continuity requirement.

The incoming MAH should obtain sufficient information to understand:

• relevant PSUR history;
• previous PSUSA outcomes;
• open regulatory commitments;
• safety concerns;
• RMP status;
• product-information changes;
• and outstanding implementation activities.

The transfer should therefore be managed as a pharmacovigilance and regulatory continuity process rather than merely as an administrative ownership change.

42. New Indication After a PSUSA

A new indication can materially change the population exposed to the medicinal product and the clinical context in which risks and benefits are evaluated.

The MAH should therefore assess the implications for:

• the safety profile;
• benefit-risk evaluation;
• RMP;
• product information;
• signal management;
• and future PSUR reporting.

The existence of a previous PSUSA conclusion does not remove the need to evaluate new evidence generated by the new indication.

43. Divergence Between EU and International Regulatory Actions

The same safety issue can lead to different regulatory actions in different jurisdictions.

This may occur because of differences in:

• authorised indications;
• populations;
• regulatory frameworks;
• available evidence;
• product information;
• or timing of regulatory review.

An EU PSUSA should therefore be considered alongside relevant international regulatory information, while the EU regulatory conclusion remains governed by the applicable EU framework.

A difference between jurisdictions should be documented and scientifically understood rather than automatically treated as an inconsistency requiring one system to copy another.

44. International Regulatory Action as PSUR Evidence

Significant safety-related actions by non-EU authorities can be relevant to the PSUR when they contribute to understanding the safety profile or benefit-risk balance.

Examples can include:

• product-information changes;
• safety communications;
• restrictions of use;
• additional monitoring requirements;
• or other significant regulatory measures.

The MAH should evaluate the underlying evidence and regulatory rationale rather than merely listing the foreign action.

45. Follow-Up After a PSUSA

The regulatory process does not necessarily end when the PSUSA conclusion is published or adopted.

Follow-up may include:

• implementation of product-information changes;
• regulatory submissions;
• RMP updates;
• additional studies;
• additional risk minimisation;
• safety communications;
• monitoring of effectiveness;
• and inclusion of the outcome in subsequent periodic safety evaluations.

Each action should have an accountable owner and appropriate evidence of completion.

46. Feeding the Outcome Into the Next PSUR

A PSUSA outcome becomes part of the cumulative safety knowledge for future reporting.

The next PSUR should therefore be able to explain, where relevant:

• what was concluded previously;
• what actions were taken;
• what evidence became available subsequently;
• whether the action was effective;
• and whether the new information changes the previous conclusion.

This creates continuity between successive reporting cycles.

The PSUR process should therefore be viewed as a longitudinal safety-evaluation system, not a sequence of isolated reports.

47. Practical Scenario: New Evidence After a PSUSA Conclusion

Suppose a PSUSA concludes that a suspected risk does not require a regulatory change. Six months later, a large observational study provides new evidence supporting an association.

The MAH should not wait passively for the next PSUR if the new evidence requires earlier assessment.

The appropriate signal-management and regulatory processes should be initiated according to the circumstances.

The subsequent PSUR can then provide the cumulative context and document how the new evidence changed the assessment.

48. Practical Scenario: PSUSA Outcome Requires Additional Risk Minimisation

Suppose the regulatory outcome requires an additional risk-minimisation measure.

The implementation process should establish:

1. the exact regulatory requirement;
2. affected products and populations;
3. responsible functions;
4. regulatory submission requirements;
5. implementation deadlines;
6. communication requirements;
7. effectiveness measures where applicable;
8. and evidence of completion.

The organisation should distinguish implementation from effectiveness.

A measure can be implemented correctly and still fail to achieve its intended effect.

49. Practical Scenario: The Outcome Appears to Conflict With the RMP

Suppose the PSUSA outcome identifies a risk that is not adequately reflected in the current RMP.

The organisation should perform a controlled impact assessment rather than treating the PSUSA document as a standalone regulatory record.

The assessment should determine whether changes are required to:

• the safety specification;
• pharmacovigilance activities;
• risk-minimisation measures;
• missing information;
• or other RMP components.

The rationale should be documented even when the conclusion is that no RMP update is necessary.

50. Practical Scenario: Multiple Products With Different Product Information

Suppose several products containing the same active substance have different product information because of different authorisation histories.

A PSUSA may identify a common safety issue, but implementation can require product-specific regulatory action.

The organisation should therefore map the regulatory outcome against the actual wording and authorisation status of each affected product.

A generic implementation statement such as "product information updated" is insufficient if it cannot demonstrate which products were changed and how.

51. Regulatory Convergence and Remaining Differences

One of the benefits of coordinated assessment is greater consistency across the EU.

However, coordinated assessment does not mean that every product must become identical in every respect.

Legitimate differences can remain where they reflect:

• different indications;
• different populations;
• different formulations;
• different authorised conditions;
• or other legally relevant distinctions.

The organisation should therefore distinguish an intended product-specific difference from an unexplained regulatory inconsistency.

52. Documentation and Records Management

PSUSA-related records should be maintained so that the organisation can reconstruct the regulatory history.

A useful record structure can link:

PSUSA identifier
      ↓
PSUR submission
      ↓
Regulatory correspondence
      ↓
Assessment report
      ↓
Recommendation / decision
      ↓
Impact assessment
      ↓
Implementation records
      ↓
Effectiveness / follow-up

The exact document-management implementation will depend on the organisation's quality system.

The essential requirement is traceability.

53. Metrics and Management Oversight

Useful management information can include:

• PSUSA submissions completed on time;
• regulatory questions answered within required timelines;
• actions implemented by deadline;
• overdue regulatory commitments;
• product-information changes completed;
• RMP updates completed where required;
• and effectiveness assessments completed where applicable.

Metrics should support management oversight rather than become a substitute for scientific assessment.

A process can have excellent on-time metrics while producing weak scientific evaluations.

54. What Good PSUSA Governance Looks Like

A mature system has:

• clear ownership;
• accurate regulatory calendars;
• controlled PSUR scope determination;
• reliable submission processes;
• regulatory-intelligence monitoring;
• documented scientific assessment;
• controlled correspondence;
• defined escalation routes;
• impact assessment after regulatory outcomes;
• implementation tracking;
• and QPPV oversight.

The objective is not administrative perfection. It is to ensure that significant regulatory safety information is translated reliably into action where required.

55. Inspection Case: The Organisation Knows the Outcome but Cannot Show Implementation

An inspector may ask when a PSUSA outcome was implemented.

If the organisation can identify the outcome but cannot produce evidence showing:

• who assessed the impact;
• which products were affected;
• what actions were required;
• when they were completed;
• and how completion was verified,

then the organisation has a traceability weakness.

The absence of a single perfect tracker is not itself the issue. The issue is whether the evidence demonstrates effective control.

56. Inspection Case: Different Internal Teams Have Different Conclusions

An inspector may find that Regulatory Affairs considers a PSUSA action complete while Pharmacovigilance considers it still open.

This can indicate a cross-functional governance failure.

The organisation should have a common controlled understanding of:

• the regulatory requirement;
• required actions;
• owners;
• deadlines;
• completion criteria;
• and escalation status.

57. Inspection Case: Previous PSUSA Outcome Was Not Considered in the Next PSUR

If a previous PSUSA identified an important concern, the next PSUR should normally be able to demonstrate how subsequent evidence and actions were considered.

Failure to establish this continuity can make the periodic reporting process appear to consist of disconnected documents rather than cumulative safety evaluation.

The organisation should therefore preserve the relationship between historical regulatory conclusions and current safety assessments.

58. Final QPPV Questions

For significant PSUSA activity, the QPPV should be able to obtain credible answers to:

• What was the regulatory issue?
• What evidence supported the outcome?
• Which products were affected?
• What did the MAH conclude?
• What did the regulator conclude?
• What changed as a result?
• Were the RMP and product information assessed?
• Were required actions completed?
• Was effectiveness evaluated where necessary?
• Has the outcome been incorporated into subsequent PV activities?

These questions provide a practical test of whether PSUSA governance is functioning as an integrated PV process.

59. Key Takeaways

PSUSA should be managed as a complete regulatory lifecycle rather than as a submission event.

The important controls extend from identifying the correct procedure through scientific assessment, regulatory outcome, implementation and subsequent follow-up.

Changes in products, indications, MAHs and regulatory environments can alter the implications of a previous conclusion. International regulatory actions can provide relevant evidence but do not replace the EU regulatory framework.

The strongest systems preserve a clear chain of evidence from the original PSUR through the regulatory assessment and into product-level implementation and future periodic safety evaluation.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VII — Periodic Safety Update Report.
2. European Medicines Agency. Periodic safety update reports (PSURs) and PSUR Single Assessment (PSUSA).
3. European Medicines Agency. European Union reference dates (EURD) list.
4. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC).
5. European Commission. Commission Implementing Regulation (EU) No 520/2012, as amended.
6. Directive 2001/83/EC, as amended.
7. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article is an educational explanation of PSUR Single Assessment and related EU procedures. It does not replace current EU legislation, GVP Module VII, EMA procedural guidance, the current EURD list, PSUR Repository requirements or an organisation's approved procedures.

Regulatory procedures and guidance may change. Before preparing, submitting or implementing a PSUR or PSUSA outcome, the current applicable regulatory documents and procedural requirements should be verified.

Examples and inspection considerations are illustrative unless an authoritative source is specifically identified.